Trials / Recruiting
RecruitingNCT04906928
Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research
Evaluation of the Performance of a 3D FGAPSIR Sequence by MRI in the Detection and Characterization of Spinal Cord Injuries in Patients With Multiple Sclerosis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
* verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence. * 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)
Detailed description
* verification of inclusion and non-inclusion criteria * information and collection of consent * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence. * 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI | * standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), 3D STIR and 3D PSIR sequence. * 3D FGAPSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 40 minutes (instead of 30 minutes) |
Timeline
- Start date
- 2023-10-25
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2021-05-28
- Last updated
- 2026-01-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04906928. Inclusion in this directory is not an endorsement.